Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer. Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a dominant off-switch while other receptors such as PD-1 and LAG-3 seem to serve more subtle rheostat functions. However, the extent of synergy and cooperative interactions between inhibitory pathways in cancer remain largely unexplored. Here, we reveal extensive coexpression of PD-1 and LAG-3 on tumor-infiltrating CD4 þ and CD8 þ T cells in three distinct transplantable tumors. Dual anti-LAG-3/anti-PD-1 antibody treatment cured most mice of established tumors that were largely resistant to single antibody treatment. Despite minimal immunopathologic sequelae in PD-1 and LAG-3 single knockout mice, dual knockout mice abrogated self-tolerance with resultant autoimmune infiltrates in multiple organs, leading to eventual lethality. However, Lag3 À/À Pdcd1 À/À mice showed markedly increased survival from and clearance of multiple transplantable tumors. Together, these results define a strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens. In addition, they argue strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.
Introduction
T-cell-mediated antitumor immune responses are essential for effective deletion of primary tumor lesions and for protection against metastases (1) . Although the immune system can detect and destroy malignant cells, tumors escape surveillance by a variety of cell intrinsic and extrinsic mechanisms (1) (2) (3) . As with chronic viral infection (4), tumor antigen-specific CD4 þ and CD8 þ T cells display impaired effector function and an exhausted phenotype characterized by decreased production of proinflammatory cytokines and hyporesponsiveness to antigenic restimulation (5) . This is mediated by cell extrinsic mechanisms, such as regulatory T cells (T reg ), and cell intrinsic mechanisms, such as inhibitory molecules that are upregulated on exhausted, tumor-infiltrating lymphocytes (TIL). In combination, these inhibitory mechanisms represent a formidable barrier to effective antitumor immunity (6) (7) (8) (9) (10) . Inhibitory receptors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD152), lymphocyte-activation gene 3 (LAG-3, CD223), and programmed cell death 1 (PD-1, CD279) function at multiple levels to ensure appropriate T-cell homeostasis, activation, and differentiation (7, (11) (12) (13) (14) (15) (16) (17) . Furthermore, all 3 inhibitory molecules also contribute to cell extrinsic regulation by controlling T reg homeostasis and function, mediating induced T reg development, and mitigating dendritic cell differentiation and function (13-16, 18, 19) . Data from genetically manipulated mice indicate that CTLA-4 represents a basic and indispensible "off switch," whereas PD-1 and LAG-3 play more subtle roles in immune regulation. Whereas Ctla4 À/À mice develop a severe lymphoproliferative disease and are usually moribund by 3 to 4 weeks of age (20) , Pdcd1
À/À (which encodes PD-1) mice live beyond 1 year while developing subtle and variable immune-based disease manifestations depending on genetic background; Pdcd1 À/À BALB/c mice develop dilated cardiomyopathy 5 to 30 weeks of age, whereas Pdcd1 À/À C57BL/6 mice develop a protracted lupus-like condition that takes over 6 months to develop (21, 22) . Unmanipulated Lag3 À/À C57BL/6 mice do not develop any disease manifestations within the first year of life (23) . Recent studies have revealed that LAG-3 and PD-1 are coexpressed on tolerized TILs suggesting that they may contribute to tumor-mediated immune suppression (5, 24) . Preclinical models using antibody treatment to block LAG-3 for cancer treatment show enhanced activation of antigen-specific T cells at the tumor site and disruption of tumor growth (25) . Abrogation of PD1 signaling in mice leads to enhanced CTL killing, cytokine production, and tumor-bearing animal survival over several different tumor models (26) . On the basis of their roles in T-cell inhibition and antitumor immune regulation, individual antibody blockade of both CTLA-4 and PD-1 have been reported to show clinical utility (27, 28) . Given this information, LAG-3 and PD-1 represent a potentially beneficial pairing for dual pathway blockade in cancer therapy. However, little is known about the extent of cooperative interaction between these regulatory pathways, information critical to the development of combinatorial immunotherapy based on simultaneous blockade of multiple receptors or ligands. In this study, we investigate whether there is synergy between LAG-3 and PD-1 by analysis of tumor growth and clearance in blocking antibody-treated mice and Lag3
Pdcd1
À/À mice.
Materials and Methods
Mouse strains and cell lines C57BL/6 mice were purchased from The Jackson Laboratory. Flow cytometry, intracellular cytokine staining, and cytokine analysis Single-cell suspensions were prepared from spleens, inguinal, brachial, and axillary lymph nodes, and tumors. Cells were stained with fluorescent-labeled antibodies (BioLegend, BDBioscience Pharmingen, or eBiosciences) and analyzed by either FACSCalibur or LSR II flow cytometer (BD). The following clones were used: CD4 (GK1.5), CD8a (53-6.7), CD11c (N418), CD25 (PC61), CD44 (IM7), CD45R/B220 (RA3-6B2), CD69 (H1.2F3), PD-1 (RMP1-30), TCR-b (H57-597), Thy1.1 (HIS51), IFN-g (XMG1.2), TNF-a (MP6-XT22), IL-17 (TC11-18H10), Foxp3 (150D), and LAG-3 (4-10-C9; ref. 31) . For intracellular cytokine staining, cells were activated with phorbol 12-myristate 13-acetate (PMA; 100 ng/mL) plus ionomycin (500 ng/mL) for 4 hours in the presence of GolgiPlug (32), processed with a Cytofix/Cytoperm kit (32) , and stained as indicated. Measurement of IFN-g, TNF-a, and MCP-1 in serum was determined by IFN-g-or TNF-a-specific ELISA kits (eBioscience) and a MCP-1-specific bead based kit (Millipore).
Tumor growth experiments and TIL preparation B16 melanoma and MC38 colon adenocarcinoma models were carried out as previously described with some modifications (33, 34 þ cells were depleted from splenocytes and lymph node cells with biotinylated anti-CD4 or anti-CD8 by macrophage separation using streptavidin-coupled beads (Milteny Biotec) to achieve purity above 95%.
Histopathology
Full necropsies were completed independently at St Jude Children's Research Hospital and Johns Hopkins. Tissues from knockout and control mice were fixed in 10% neutral buffered formalin, except eyes, which were fixed for 24 hours in Davidson's fixative, embedded in paraffin, sectioned at 4 mm and stained with hematoxylin and eosin for histopathologic examination. Collagen deposition was detected by a Masson's Trichrome stain. Macrophages and T cells were detected using rat anti-mouse MAC2 (CL8942AP; Accurate Chemical) and goat anti-human CD3 (sc-1127; Santa Cruz Biotechnology) antibodies, respectively. Heat-induced epitope retrieval was carried out by heating slides in ER2 (AR9640; Leica) for 30 minutes and the Refine system (DS9800; Leica Microsystems) used for detection. T reg cells were detected with a rat anti-mouse FoxP3 antibody (14-5773-82; eBioscience) with heat-induced retrieval, pH 6.0, target retrieval buffer (S699; Dako) followed by a horseradish peroxidase-labeled streptavidin detection system (TS-125-HR; Thermo Shandon). In all immunohistochemical assays, 3,3 0 -diaminobenzidine was used as the chromogenic substrate with a light hematoxylin counterstain.
Autoantibody analysis
Mouse sera were analyzed by indirect ELISA, alongside a positive control (serum from a MRL/lpr mouse, a SLE disease model), using 96-well Nunc MaxiSorp plates (Nalgene Nunc). Multiple antigen blot assay (MABA) was conducted as described (38) .
Clone 4 TCR transgenic T-cell experiments
CL4 adoptive transfer and in vivo CTL studies were carried out as previously described (25, 39) .
Statistical analyses
Summary statistics are presented as mean AE SEM. Group means were compared with 2-sample t tests. Event-free survival (moribund) estimates were calculated with the KaplanMeier method; mouse groups were compared by log-rank test. The proportions of tumor-free mice were evaluated with the binomial distribution; synergy hypotheses were tested based on the maximum likelihood method. Trends in weight over time and tumor growth over time among different mice groups were analyzed using mixed models. All P values are 2-sided, and statistical significance was assessed at the 0.05 level. Analysis was conducted by SAS (version 9.2).
Results
Combinatorial anti-LAG-3/anti-PD-1 immunotherapy inhibits tumor growth PD-1 monoclonal antibody treatment has shown clinical efficacy against multiple malignancies including melanoma, prostate, renal cell, and lung cancer (27) . LAG-3 has been suggested to directly modulate the activity of PD-1 þ cells (5); furthermore, coexpression of LAG-3 and PD-1 has been shown in malignant mouse and human tissue (5, 24) . Given these data, we hypothesized that LAG-3 and PD-1 act synergistically to control immune homeostasis and mediate tumor-induced tolerance. Consistent with previous reports, a significant percentage of CD4 þ and CD8 þ TILs from transplanted B16 melanoma, MC38 colorectal adenocarcinoma, and Sa1N fibrosarcoma expressed high levels of LAG-3 and PD-1 (32, 34), whereas similar upregulation was not observed on peripheral T-cell populations (Fig. 1) . Next, we asked if antibody-mediated dual blockade of these pathways would reduce tumor growth by assessing the potential efficacy of combined anti-LAG-3 and anti-PD-1 blockade in mice with established tumors. Reduced growth of Sa1N fibrosarcoma and MC38 colorectal adenocarcinoma (32, (40) (41) (42) was observed in some but not all mice treated with the anti-LAG-3 or anti-PD-1 monotherapy (Fig. 2) ; only a few mice were tumor free after 50 days (0%-40%). For anti-LAG-3, this is the first demonstration of TGI with anti-LAG-3 as a monotherapy. In striking contrast, 70% and 80% of the Sa1N-and MC38-inoculated mice, respectively, were tumor free after 50 days following combinatorial anti-LAG-3/anti-PD-1 immunotherapy (Fig. 2) . However, this regimen had no effect against established B16 tumors. Using the maximum likelihood method, there seemed to be a synergistic benefit of anti-LAG-3/anti-PD-1 combinatorial immunotherapy that is superior to either the additive effect of anti-LAG-3 and anti-PD-1 or monotherapy. Dual treatment with anti-LAG-3/anti-PD-1 did not result in immunopathologic manifestations such as lymphocytic infiltration in the Sa1N fibrosarcoma model as determined by detailed histologic analysis of multiple tissues. Despite efficient tumor clearance, no evidence of systemic or organ-specific autoimmunity was observed.
To investigate the mechanism underlying decreased tumor growth in antibody-treated mice, MC38 tumor-bearing mice were treated with the antibody combinations used above and draining lymph node (DLN) T cells, non-DLN (NDLN) T cells, and TILs analyzed by flow cytometry for phenotype and effector function. As expected, average tumor size of anti-PD1-treated or dual antibody-treated mice was significantly smaller than isotype control or anti-LAG3-treated mice ( Supplementary Fig. S1 ). A significantly higher percentage of IFN-g þ CD8 þ T cells were found in the tumor-associated DLNs of dual antibody-treated mice compared with the monotherapy groups, or cells analyzed from NDLNs (Fig. 3A) . Likewise, a in anti-LAG-3/anti-PD-1-treated mice than in control groups (Fig. 3B) . Taken together, these data suggest that anti-LAG-3/ anti-PD-1 combinatorial immunotherapy may act synergistically to reduce tumor growth by increasing the proportion of effector T cells in the tumor and DLNs.
Lag3
À/À Pdcd1 À/À mice develop lethal systemic autoimmunity To further investigate the synergy between these 2 inhibitory molecules, we next assessed whether LAG-3 and PD-1 cooperate to control immune homeostasis and mediate tumorinduced tolerance with a genetic approach. Lag3 À/À Pdcd1 À/À C57BL/6 or B10.D2 mice were generated at 2 independent (Fig. 4A and Supplementary Fig. S2 ). The major histopathologic manifestations included diffuse fibrosing lymphohistiocytic endocarditis, myocarditis, and pancreatitis (Fig. 4B , Supplementary (Fig. 4C, Supplementary Fig. S5 ). These cells possessed a predominantly activated/memory phenotype as indicated by CD69/CD44 staining. Nevertheless, there seemed to be minimal difference in the extent of division in vivo based on ex vivo Ki67 staining, even though Lag3 Research. Research. S8 ). Collectively, these data suggest that the loss of LAG-3 and PD-1 also results in loss of tolerance to a model self-antigen.
Reduced tumor growth and enhanced survival in Lag3
To continue our analysis of Lag-3/PD-1 synergy in the regulation of antitumor immunity, we assessed tumor growth in Lag3 À/À Pdcd1 À/À mice and controls over time. Of the 3 transplantable tumor models examined in this study, B16 is regarded as the least immunogenic and thus the hardest to eliminate by immunologic intervention (32, 34) . A low dose of B16 cells (1.25 Â 10 5 ) progressively grew in wild-type and Lag3
À/À mice inoculated intradermally at day 0, whereas limited growth was observed in Pdcd1 À/À and Lag3 À/À Pdcd1 À/À mice ( Supplementary Fig. S9A ). Although previous studies suggested that PD-1 deletion did not affect subcutaneously injected tumor growth (44), our experiments revealed reduced tumor growth in Pdcd1 À/À mice compared with wild-type mice. Paradoxically, Lag3 À/À mice developed slightly larger tumors. Whether this is due to reported defects in natural killer cell cytolysis (23) , or an unexpected role of pDCs, which highly express LAG-3 (45), remains to be determined. Statistical analysis with the maximum likelihood method for synergy found that the lack of tumor growth in the Lag3 À/À Pdcd1 À/À mice was greater than the additive effects of tumor growth in Lag3 À/À mice and Pdcd1 À/À mice at day 11 (P < 0.05) and day 13 (P < 0.0005) suggesting that LAG-3 and PD-1 synergize to mediate tumor-induced tolerance. Depletion of CD4 þ and CD8 þ T cells restored normal B16 tumor growth in compound-deficient mice, indicating the necessity of adaptive immunity to the antitumor response ( Supplementary Fig. S9B ).
As the difference in resistance to B16 growth between Pdcd1 À/À and Lag3 À/À Pdcd1 À/À mice seemed small, we evaluated tumor B16 and MC38 growth at different doses. At the higher B16 dose (5 Â 10 5 cells per mouse), wild-type and Lag3 À/À mice show uncontrolled tumor growth and lethality with an average survival time of less than 20 days (Fig. 5A and Supplementary Fig. S10 ). Lag3 À/À Pdcd1 À/À mice (80%) eliminated tumors compared with only 40% of Pdcd1 À/À mice; however, B16 survivors did not display autoimmune vitiligo as is often seen with this model (46) . We also investigated growth of subcutaneously implanted MC38 adenocarcinoma cells at 2 different doses. Whereas MC38 growth and survival were and WT littermate controls. Moribund curves were analyzed for statistical significance by log-rank test; ÃÃÃ , P < 0.001. B, representative histopathology of the heart and pancreas of WT and Lag3
mice. C, number of various T-cell populations in the spleen and LNs (inguinal and brachial) is shown. Data represent 3 to 4 independent experiments with 4 to 7 mice total per group (5-to 7 weeks old). Error bars represent SEM; Ã , P < 0.05; ÃÃ , P < 0.01 (unpaired t test).
comparable in Lag3
À/À Pdcd1 À/À and Pdcd1 À/À mice when a low dose (2 Â 10 5 cells per mouse) was used (70% vs. 71%, respectively; Fig. 5B and Supplementary Fig. S10 ), Lag3 À/À Pdcd1 À/À mice were clearly more effective at preventing high-dose (5 Â 10 5 cells per mouse) MC38 tumor growth and ensuring survival (83% vs. 38%, respectively; Fig. 5C and Supplementary Fig. S10 ). Phenotypic analysis revealed enhanced IFN-g expression by Lag3
À/À Pdcd1 À/À CD4 þ and CD8 þ T cells in tumor DLNs compared with wild-type and Lag3 À/À mice, and NDLNs from all groups (Fig. 6 ). These data suggest that combined loss of LAG-3 and PD-1 limits tumor-mediated tolerization and enhances tumor-specific immunity and resistance to tumor growth. To further investigate the killing efficacy of Lag3 Fig. S11 ). These data support the conclusion that Lag3 
Discussion
The data presented here illustrate clear synergy between the inhibitory receptors LAG-3 and PD-1 in controlling immune homeostasis, preventing autoimmunity, and enforcing tumorinduced tolerance. First, we show coexpression of LAG-3 and PD-1 on tumor-infiltrating lymphocytes. Second, we show that dual blockade of these receptors leads to decreased tumor growth and enhanced antitumor immunity. Importantly, dual antibody-treated mice show more robust immune responses than either single-treated group. Third, analysis of mutant mice revealed a cooperative requirement for LAG-3 and PD-1 in maintaining immune homeostasis. Consistent with our observations following antibody-mediated blockade of LAG-3 and PD-1, Lag3 À/À Pdcd1 À/À mice prevented growth of highdose B16 and MC38 tumors and ensured survival while single knockout controls and wild-type mice succumbed to disease. Taken together, these data reveal an unappreciated synergistic cooperation between LAG-3 and PD-1 in limiting tumor growth.
Although anti-LAG-3/anti-PD-1 combinatorial immunotherapy effectively cleared established Sa1N and MC38 tumors, this therapy was not effective against established B16 tumors. In contrast, B16 tumors were more difficult to establish in Lag3 À/À Pdcd1 À/À mice. B16 is a more difficult tumor to eradicate than MC38 and Sa1N and thus there could be several possible explanations for this apparent discrepancy. First, expression of LAG-3/PD-1 on TILs from B16 is lower than for MC38 and Sa1N, and this may be below a required threshold for efficacy upon antibody blockade in tumor-bearing mice. Second, as the knockout mice would lack LAG-3/PD-1 at the initiation of tumor inoculation, the immune system would not have this impediment at the commencement of an antitumor response. In contrast, the initial stages of LAG-3/PD-1 upregulation may already have occurred in tumor-bearing mice at the time of antibody treatment thereby establishing sufficient tolerance to prevent effective antitumor immunity. Third, there may be additional regulatory mechanisms that contribute a greater role with B16 that may be sufficient to prevent antitumor immunity when LAG-3/PD-1 blockade is initiated in mice that already have tumors. Lastly, we cannot rule out the possibility that the genetic deletion of LAG-3/PD-1 results in T regs that have a cell intrinsic defect in their regulatory capacity which impacts early tumor establishment. Of course, a combination of these issues could also contribute to the difference in B16 clearance seen in LAG-3/PD-1 deficiency versus late stage antibody-mediated blockade. It is possible that alternate dosing regimens and therapeutic combinations could result in effective clearance of established B16 with anti-LAG-3/anti-PD-1 combinatorial immunotherapy. It is noteworthy that the percentage of IFN-g þ TILs is higher in Lag3 À/À Pdcd1 À/À mice versus anti-LAG-3/anti-PD-1-treated mice (Fig. 6 vs. Fig. 3 ). These differences could be reflective of the differences in B16 elimination in LAG-3/ PD-1-deficient versus mAb-treated mice. Alternatively, as discussed above, these observations could be due to the different tumors analyzed or temporal differences between these experiments, as IFN-g expression was determined 1 week after mAb treatment compared with 2 weeks after tumor inoculation into Lag3 (47) . Heart-infiltrating T cells from these compound-deficient mice were shown to produce high amounts of IFNg compared with distal lymphoid organs such as the spleen. Our results are consistent with their data, as we also observed enhanced production of proinflammatory cytokines by T cells infiltrating sites of inflammation, such as the heart and pancreas in Lag3 À/À Pdcd1 À/À mice and in tumors and DLNs in knockout and antibody-treated mice. Furthermore, the Honjo group also observed accelerated autoimmune diabetes in NOD mice expressing a loss-offunction LAG-3 mutant, consistent with our recent observations in Lag3 À/À NOD mice (48) . However, the mice used by
Honjo and colleagues that lacked functional LAG-3/PD-1 expression were on a BALB/c background, whereas our data were derived from mice on a C57BL/6 or B10.D2 background. Strain-specific differences between these mice have been well documented (49, 50) and may have contributed to subtle differences in phenotypic and mechanistic observations reported. For instance, loss of LAG-3/PD-1 on a B10.D2 background can lead to an increase in IL-17 þ cells which was not seen in mice on a Balb/c background. Although CTLA-4, PD-1, and LAG-3 are all negative regulators expressed during T-cell activation, high level, dual LAG-3/ PD-1 expression is largely restricted to infiltrating TILs. Thus, LAG-3/PD-1 combinatorial immunotherapy may promote tumor-specific responses relative to nonspecific or self-antigen-specific immune responses and thus may be less toxic than CTLA-4 blockade. Given the recent phase 3 results with anti-CTLA-4 treatment of patients with metastatic melanoma, showing a clear survival benefit (albeit with notable immune toxicity; ref. 28), our results suggest that combined blockade of PD-1 and LAG-3 is a highly promising combinatorial strategy for the immune-based therapy of cancer.
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